Al-Ahmadi A et al. Next generation sequencing of advanced non-small cell lung cancer: Utilization based on race and impact on survival. Clin Lung Cancer 2021;22(1):16-22.e1. Abstract
Chaft JE et al. Clinical outcomes of patients with resected, early-stage ALK-positive lung cancer. Lung Cancer 2018;122:67-71. Abstract
Dimou A et al. MET gene copy number predicts worse overall survival in patients with non-small cell lung cancer (NSCLC); A systematic review and meta-analysis. PLoS One 2014;9(9):e107677. Abstract
Felip E et al. Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB-IIIA non-small-cell lung cancer (IMpower010): A randomised, multicentre, open-label, phase 3 trial. Lancet 2021;398(10308):1344-57. Abstract
Gelatti ACZ et al. Real-world prevalence of PD-L1 expression among tumor samples from patients with non-small-cell lung cancer. Clin Lung Cancer 2020;21(6):e511-5. Abstract
Guérin A et al. Brain metastases in patients with ALK+ non-small cell lung cancer: Clinical symptoms, treatment patterns and economic burden. J Med Econ 2015;18(4):312-22. Abstract
Hendriks LE et al. Oncogene-addicted metastatic non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol 2023;34(4):339-57. Abstract
Hofman P et al. Current challenges and practical aspects of molecular pathology for non-small cell lung cancers. Virchows Arch 2024;484(2):233-46. Abstract
Jordan EJ et al. Prospective comprehensive molecular characterization of lung adenocarcinomas for efficient patient matching to approved and emerging therapies. Cancer Discov 2017;7(6):596-609. Abstract
Kerr KM et al. The evolving landscape of biomarker testing for non-small cell lung cancer in Europe. Lung Cancer 2021;154:161-75. Abstract
Le T, Gerber DE. ALK alterations and inhibition in lung cancer. Semin Cancer Biol 2017;42:81-8. Abstract
Leonetti A et al. Phase II, open-label, single-arm, multicenter study to assess the activity and safety of alectinib as neoadjuvant treatment in surgically resectable stage III ALK-positive NSCLC: ALNEO trial. Clin Lung Cancer 2021;22(5):473-7. Abstract
Marks S, Naidoo J. Antibody drug conjugates in non-small cell lung cancer: An emerging therapeutic approach. Lung Cancer 2022;163:59-68. Abstract
O’Brien M et al. Pembrolizumab versus placebo as adjuvant therapy for completely resected stage IB-IIIA non-small-cell lung cancer (PEARLS/KEYNOTE-091): An interim analysis of a randomised, triple-blind, phase 3 trial. Lancet Oncol 2022;23(10):1274-86. Abstract
Penault-Llorca F et al. Expert opinion on NSCLC small specimen biomarker testing - Part 2: Analysis, reporting, and quality assessment. Virchows Arch 2022;481(3):351-66. Abstract
Pi C et al. EGFR mutations in early-stage and advanced-stage lung adenocarcinoma: Analysis based on large-scale data from China. Thorac Cancer 2018;9(7):814-9. Abstract
Rangachari D et al. Brain metastases in patients with EGFR-mutated or ALK-rearranged non-small-cell lung cancers. Lung Cancer 2015;88(1):108-11. Abstract
Shaw AT et al. Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: A retrospective analysis. Lancet Oncol 2011;12(11):1004-12. Abstract
Shi D et al. Chimeric antigen receptor-glypican-3 T-cell therapy for advanced hepatocellular carcinoma: Results of phase I trials. Clin Cancer Res 2020;26(15):3979-89. Abstract
Solomon BJ et al. First-line crizotinib versus chemotherapy in ALK-positive lung cancer. N Engl J Med 2014;371(23):2167-77. Abstract
Wang J et al. Detection of ALK protein expression in lung squamous cell carcinomas by immunohistochemistry. J Exp Clin Cancer Res 2014;33(1):109. Abstract
Yaegashi LB et al. In situ overexpression of matricellular mechanical proteins demands functional immune signature and mitigates non-small cell lung cancer progression. Front Immunol 2021;12:714230. Abstract